29.06 (-%)
As of Feb 23, 2023
Source:
We are a clinical-stage biopharmaceutical company focused on developing our lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases. CIN-107 is a highly selective, oral small molecule inhibitor of aldosterone synthase, the enzyme responsible for the synthesis of aldosterone in the adrenal gland. CIN-107 inhibits aldosterone synthase activity, providing a differentiated mechanism for lowering aldosterone activity via a reduction of aldosterone synthesis, with the goal of providing an improved treatment for patients suffering from hypertension, or high blood pressure. We are conducting multiple Phase 2 clinical trials using CIN-107 in differing populations of patients, all of whom are hypertensive.
Country | United States |
Headquarters | waltham, massachusetts |
Phone Number | 8445311834 |
Industry | |
CEO | Marc De Garidel |
Website | cincor.com |